Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Extramedullary relapse in high risk patients

  • B Moiraghi
  • B Moiraghi's Avatar Topic Author
10 years 9 months ago #520 by B Moiraghi
Extramedullary relapse in high risk patients was created by B Moiraghi
42 year old male with CML diagnosed in CF (since February 2012, Sokal high risk , he began treatment, with 2º G TKI Dasatinib 100 mg (Sprycel) At 6 months he was in CCR and MMR (IS) , he had mild adverse event, he never discontinued the treatment.
Since December 2012, he had cervical adenomegaly bilateral, a biopsy was made in May 2013 (he was in HR, CCR and MMR)the adenopaty biopsy is CML (Granulocitic Sarcoma), pending the inmunofenotype.
The patient was in good perfomance
Any feedback regarding treatment would be much appreciated.
Thanks
Quick Reply

Reply to B Moiraghi

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar Topic Author
10 years 9 months ago #521 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic Re: Extramedullary relapse in high risk patients
I think that he should be treated as an advanced phase. Please have a look at the mutations in the RNA extracted from the biopsy and, if you can, also at a cytogenetic analysis (but probably this is more difficult). Then I would probably introduce chemo + TKI if possible (according to the mutation analysis) and then eventually proceed to SCT as he is very young. If SCT transplant cannot be performed, maybe I would also consider radiation therapy on the involved lymphonodes But just to start, to obtain the mutation analysis is important.
Quick Reply

Reply to Giuseppe Saglio

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene